Key Links

Keylinks Right Menu 

Licensure Key Links

Keylinks Licensure

State & Federal Action Notices

OPH State Lab Forms Now Available Electronically: Updated Guidance for COVID-19 Testing at the State Laboratory

The use of Telemedicine Technologies with Established Patient

(LA HAN)--Updated Guidance for COVID-19 Testing at the State Lab & Patient Under Investigation Form

Notice to COVID-19 Temporary Permit Holders

Heroine: A Deadly Resurgeance

Telehealth for Allied Health Care Providers

Continuing Education Tracker Update

Policies

Board Buzz Newsletters

Whistleblowing

Private Radiological Technologists

Podiatrists

Multi-Specialty Conference on Sarcoidosis

25% Decrease in opioid production in 2017

Special Call Meeting

Louisiana Department of Health Reporting Surge of Fatal Drug Overdoses

Scammers claiming to be with the LSBME

Investigations

Application & Instructions for Initial Licensure - Podiatry

Online Board Orientation

COVID-19 CRISIS INFORMATION

Board Approved CME Courses for CDS Requirements

LA State Registers-5 Year Archive

Links

Welcome Medical Psycologists

Frequently Asked Questions

Health Care Resources for the Practitioner

Application & Instructions for Initial Licensure - Physician's Reinstatement

Activity

Application & Instructions for Initial Licensure - Polysomnography Reinstatement

Emergency Temporary Permits for Health Care Practitioners

GETP and PGY Temporary Permits

History

Educational Resources - Physicians

Topics of Interest

Helpful Hints - Physician Licensure

General Instructions

Advisory Opinion FAQ's

Death Certificates

The Impaired Professional

Medical Psychology Practice Act

Frequently Asked Questions - Physician Licensure

Adjudication Process

Athletic Trainer Advisory Committee

Louisiana Telehealth Access Act

Board Orientation On-line Welcome

Email Blast Communications from the LSBME

Unprofessional Conduct Rules

LaMED DashBoard Now Available

LDH Provider Notice: Medical and Surgical Procedures

LSBME Legislative Update - 2019

Updated Interim Guidance on Evaluation and Testing Criteria for Suspected COVID-19 Cases

Interim Guidance on 2019 Novel Coronavirus (2019-nCoV) in Travelers from Wuhan, China

Health Alert Regarding Acute Flaccid Myelitis (AFM)

Medicaid Pharmaceutical and Therapeutics Committee

Hepatitis A Outbreak (Update)

Moonlighting Guidance

CDC Update re: Hepatitis A Outbreak

Guidance For Physicians On Safe Purchase Of Drugs From Pharmaceutical Distributors

Occupational Therapy Assistants

Office Based Surgery

Interstate Medical Licensure Compact

Notice to Physician Assistants

Emergency Temporary Permits

Hydrocodone Combination Products Re-Scheduled

CDC's Interim Guidance for Businesses for COVID-19

Rule Adoptions

Physicians Health Program

Integrative and Complementary Medicine Advisory Committee

Perfusionists Advisory Committee

Integrative and Complementary Medicine Committee

Advisory Committees

Perfusionists Rules

Collaborative Drug Therapy Management

LDH views on off-label prescribing

Respiratory Therapy

Healthcare Resources for the Consumer

Board Meeting - March 23-24, 2020

Infant Formula Recall and Reporting of C ronobacter sakazakii Cases in Infants

Availability of Personal Protective Equipment from your Established Vendor

USMLE Step 3 (Update)

Notice to Licensees re Continuing Education Requirements

LSMS Roundtable Discussion

Guidance for Clinicians Caring for Individuals Recently Evacuated from Afghanistan

LDH - Hepatitis C Announcement

***Scam Alert***

Renewal Notices

Louisiana Health Alert Network (LA HAN)--Steps for Community- and Faith-Based Organizations to Take to Prepare for Coronavirus

Training Matters

Physician Assistant Advisory Committee Vacancy

Zika in the ED: How Emergency Care Staff Can Take Action

Notice of a Large Mumps Outbreak in Northwest Arkansas

CDC's Guideline for Prescribing Opioids for Chronic Pain Webinar

Therapeutic Marijuana Guidance

Background Check Fee

LSBME Legislative Update

LSBME Newsletter-June 2018

Prescribers:  Please read the following to be properly informed about electronic prescribing of CDS:

Since June 1, 2010, the DEA has allowed electronic prescribing of controlled substances.  However, the electronic transmission of controlled substance prescriptions is not mandatory in Louisiana.

Paper prescriptions for all schedule II-V controlled substances are still permitted.  Telephone authorization for schedules III-V controlled substances are still valid.

Electronic prescriptions for controlled substances, including schedule II, are permitted only when both of the following criteria are met:

1. The prescriber’s software has been authenticated by a DEA–approved certifying organization; and

2. The pharmacy’s software has been authenticated by a DEA-approved certifying organization.

For a list of DEA-approved certifying organizations, go to: 

http://www.deadiversion.usdoj.gov/ecomm/e_rx/thirdparty.htm

Not all prescribers or pharmacies have approved systems.  Prescribers and pharmacies should understand the capabilities and limitations of their current software.   For more information on the various e-prescribing software vendors and their attributes, the LA Board of Pharmacy recommends the following website:  

http://surescripts.com/network-connections/mns/prescriber-software

Physicians should ensure that their prescribing software is approved for this purpose by one of the entities on the DEA certified list above.  In some cases, this may only require an upgrade of the software you are already using.  In the absence of approved software, CDS prescriptions transmitted electronically to a pharmacy are deemed to be “faxed” and will not be filled without an original signature.

1. Have a certification report for the electronic health records (EHR) or electronic prescription application to verify compliance with the DEA rule.

2. Obtain digital “credentials” to electronically sign CDS prescriptions.The prescriber may need to contact the EHR or application provider to determine how to obtain these credentials.

3. Restrict access so that only authorized individuals may electronically “sign” CDS prescriptions.

For further information please review the information available on the DEA website at:  

http://www.deadiversion.usdoj.gov/ecomm/e_rx/index.html

Electronic Prescribing of Controlled Substances